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Background: Few data are available to estimate the gain in life expectancy in patients with left ventricular systolic dysfunction who have been 
treated early with ACE inhibitor therapy. We reported here the survival outcomes of a 23-year follow-up of patients who were previously enrolled in 
the Studies of Left Ventricular Dysfunction (SOLVD) in Belgium.
Methods: 558 patients with asymptomatic or symptomatic heart failure and EF ≤35% were randomized to receive either enalapril (N=278) or 
placebo (N=280) for a median of 3.3 years. At trial closeout, all 433 survivors were treated with enalapril and followed. Long-term survival and life 
expectancy were compared between those who received early enalapril therapy and those who received delayed therapy.
Results: No patients were lost to follow-up. The median duration of alive follow-up was 21.1 (range 19.2-23.0) years from randomization or 17.9 
(17.7-18.6) years since closeout. The 5-, 10-, 15- and 20-year Kaplan-Meier survival rates were 71%, 49%, 31% and 19% for the enalapril group and 
65%, 41%, 25% and 15% for the placebo group respectively. All-cause mortality was lower in the enalapril group than in the placebo group (84% 
vs. 87%; Wilcoxon p=0.03). Early therapy with enalapril was associated with a 16% relative risk reduction in death from any cause as compared to 
delayed therapy (Cox hazard ratio 0.84; p=0.05). The benefit of enalapril was similar in the Prevention and Treatment Trials (p=0.48 for interaction). 
Initial risk reduction by enalapril derived from the original trial was sustained over the post-trial period (p=0.80 for homogeneity of hazard). Life 
expectancy was increased by a median of 28.3 (24.4 for Prevention Trial and 32.1 for Treatment Trial) months among patients treated early with 
enalapril as compared to those treated late (95% CI 7.4-53.7; p=0.006). Post-trial ACE inhibitor usage (80%) was similar between the two groups 
(p=0.38).
Conclusions: In a 23-year follow-up of the Belgian SOLVD cohort, life expectancy of patients with left ventricular systolic dysfunction was 
significantly increased among those who were treated early with enalapril as compared to those who were treated late.
